The softgel capsule market encompasses the production and distribution of specialized oral dosage forms consisting of gelatin-based shells surrounding liquid, semi-solid, or suspension fills delivering pharmaceutical drugs, dietary supplements, and cosmetic formulations. Softgel capsules combine gelatin, water, opacifiers, and plasticizers such as glycerin or sorbitol creating seamless, hermetically sealed dosage forms offering superior bioavailability, dose precision, ingredient stability, consumer convenience, and product differentiation compared to alternative delivery systems. These sophisticated delivery vehicles enable encapsulating oxygen-sensitive ingredients, lipid-based formulations, poorly water-soluble compounds, and precise dosage combinations not readily achievable through tablets or hard capsules.
The industry serves pharmaceutical manufacturers developing prescription medications, over-the-counter drug products, and specialty therapeutic formulations; dietary supplement companies producing vitamins, minerals, omega fatty acids, herbal extracts, and nutritional products; and cosmetic manufacturers creating beauty-from-within products including skincare supplements, hair and nail formulations, and anti-aging products. Manufacturing requires specialized equipment, technical expertise, stringent quality control, and regulatory compliance ensuring product safety, efficacy, and consistency.
Lonza announced in December 2024 its plan to exit its Capsules & Health Ingredients business to focus exclusively as a pure-play contract development and manufacturing organization (CDMO) for drug development and manufacturing, as part of its One Lonza strategy. Lonza entered the capsule business in 2017 through acquiring Capsugel.
In January 2022, Procaps Group, among the top five global pharmaceutical softgel producers, acquired its first United States-based softgel production facility with approximately 1.8 billion capsules per year production capacity, alongside a pharmaceutical research and development center expanding global growth of its integrated contract development and manufacturing organization (iCDMO) business unit.
Asia Pacific exhibits growth rates of 6.0%-8.5%, driven by expanding pharmaceutical manufacturing, growing dietary supplement markets, increasing healthcare spending, and rising consumer wellness awareness across China, India, Japan, and Southeast Asian countries. The region benefits from cost-competitive manufacturing, expanding middle class populations, increasing disposable incomes, and growing acceptance of preventive healthcare and dietary supplementation. China demonstrates rapid market expansion through domestic pharmaceutical production growth, expanding nutraceutical consumption, and developing contract manufacturing capabilities serving both domestic and export markets.
Europe demonstrates growth rates of 5.0%-7.0%, with established pharmaceutical industries, sophisticated dietary supplement markets, stringent regulatory standards, and strong consumer health consciousness across Germany, United Kingdom, France, and other advanced economies. The region emphasizes high-quality manufacturing, innovative formulation development, and premium product positioning. European manufacturers focus on specialty applications, advanced delivery technologies, and sustainable manufacturing practices aligned with environmental regulations and consumer preferences.
South America shows moderate growth rates of 4.5%-6.5%, with expanding pharmaceutical markets, growing dietary supplement adoption, increasing healthcare access, and rising middle class populations across Brazil, Argentina, and other countries. Procaps Group maintains significant regional presence serving pharmaceutical and nutraceutical manufacturers across South American markets.
The Middle East and Africa region exhibits growth rates of 4.0%-6.0%, with developing pharmaceutical sectors, growing dietary supplement awareness, increasing healthcare investment, and expanding consumer markets creating future growth opportunities as economic development and healthcare access improve.
Dietary supplement applications dominate softgel capsule consumption encompassing omega-3 fatty acids, vitamins and minerals, herbal extracts, probiotics, coenzyme Q10, and numerous nutritional ingredients serving health-conscious consumers. Supplements represent the largest and fastest-growing application segment driven by expanding global wellness trends, increasing preventive healthcare emphasis, growing aging populations seeking health maintenance products, rising disposable incomes enabling supplement purchases, and expanding scientific evidence supporting dietary supplementation benefits. Consumer preferences for convenient, easy-to-swallow dosage forms, precise dosing, and products free from artificial ingredients favor softgel formats.
Cosmetic applications represent emerging market segments encompassing beauty-from-within products including collagen supplements, hyaluronic acid formulations, antioxidant complexes, and specialty ingredients targeting skin health, hair quality, nail strength, and anti-aging benefits. Growth drivers include increasing consumer interest in holistic beauty approaches, expanding nutricosmetics category recognition, growing scientific support for oral beauty supplementation, and rising demand for natural and functional beauty products.
Capsugel Inc., historically a major softgel capsule manufacturer, was acquired by Lonza in 2017. Lonza announced in December 2024 its strategic decision to exit the Capsules & Health Ingredients business focusing exclusively on drug development and manufacturing services as a pure-play CDMO.
Soft Gel Technologies Inc. operates softgel contract manufacturing serving pharmaceutical, dietary supplement, and cosmetic companies requiring specialized encapsulation services. The company provides formulation development, analytical testing, and commercial production capabilities.
CAPTEK Softgel International Inc. manufactures softgel capsules and provides contract manufacturing services serving North American pharmaceutical and nutraceutical markets through specialized production capabilities and regulatory expertise.
Douglas Limited operates softgel manufacturing primarily serving United Kingdom and European markets with pharmaceutical and dietary supplement production capabilities.
Fuji Capsule Co. Ltd. manufactures softgel capsules in Japan serving domestic and international pharmaceutical and nutraceutical companies through advanced manufacturing technologies and quality systems.
Sirio Pharma Co. Ltd. sold 7,912,863,500 softgel capsules in 2024, demonstrating substantial production capacity and market presence. The Chinese manufacturer serves pharmaceutical, dietary supplement, and functional food applications through large-scale production facilities and expanding international customer relationships.
OneSource maintains annual production capacity reaching 2.4 billion capsules, ranking among top five global softgel producers. The company operates advanced manufacturing infrastructure serving pharmaceutical and nutraceutical markets.
Aenova Group provides contract development and manufacturing services for pharmaceuticals and dietary supplements including softgel production capabilities across European facilities serving global customers.
Procaps Group ranks among top five global pharmaceutical softgel producers, expanding through strategic acquisitions including January 2022 purchase of United States production facility with approximately 1.8 billion capsules annual capacity alongside research and development center strengthening integrated contract development and manufacturing organization capabilities.
Softgel manufacturing utilizes specialized rotary die encapsulation technology where gelatin ribbons are formed, filled, and sealed in continuous processes requiring precise temperature control, humidity management, and process parameter optimization. Manufacturing operations demand sophisticated capabilities including clean room environments meeting pharmaceutical production standards, advanced encapsulation equipment requiring skilled operation and maintenance, comprehensive quality control testing throughout production processes, and specialized drying and finishing operations ensuring capsule stability and quality.
Formulation development services support customers creating optimized softgel products through solubility enhancement, bioavailability improvement, stability testing, and analytical method development. Leading contract manufacturers invest substantially in technical expertise, pilot-scale equipment, and analytical capabilities supporting formulation optimization and regulatory documentation.
Quality assurance encompasses comprehensive testing including physical characterization, chemical analysis, microbiological testing, and stability studies ensuring products meet specifications and regulatory requirements. Regulatory compliance requires adherence to good manufacturing practices, quality management systems, documentation standards, and jurisdiction-specific requirements across pharmaceutical and dietary supplement applications.
Distribution channels include direct supply relationships between contract manufacturers and pharmaceutical or nutraceutical brand companies, finished product manufacturers operating internal softgel production for proprietary products, and contract packaging operations preparing finished consumer products from bulk softgel production.
This product will be delivered within 1-3 business days.
The industry serves pharmaceutical manufacturers developing prescription medications, over-the-counter drug products, and specialty therapeutic formulations; dietary supplement companies producing vitamins, minerals, omega fatty acids, herbal extracts, and nutritional products; and cosmetic manufacturers creating beauty-from-within products including skincare supplements, hair and nail formulations, and anti-aging products. Manufacturing requires specialized equipment, technical expertise, stringent quality control, and regulatory compliance ensuring product safety, efficacy, and consistency.
Lonza announced in December 2024 its plan to exit its Capsules & Health Ingredients business to focus exclusively as a pure-play contract development and manufacturing organization (CDMO) for drug development and manufacturing, as part of its One Lonza strategy. Lonza entered the capsule business in 2017 through acquiring Capsugel.
In January 2022, Procaps Group, among the top five global pharmaceutical softgel producers, acquired its first United States-based softgel production facility with approximately 1.8 billion capsules per year production capacity, alongside a pharmaceutical research and development center expanding global growth of its integrated contract development and manufacturing organization (iCDMO) business unit.
Market Size and Growth Forecast
The global softgel capsule market is projected to reach 6.5-7.5 billion USD by 2026, with an estimated compound annual growth rate of 5.5%-7.5% through 2031. This growth trajectory reflects expanding dietary supplement consumption globally, increasing pharmaceutical preference for softgel delivery systems, growing consumer wellness trends, advancing manufacturing technologies, and emerging applications in cosmetic and nutraceutical categories.Regional Analysis
North America dominates the softgel capsule market with estimated growth rates of 5.0%-7.0%, led by the United States where substantial dietary supplement consumption, advanced pharmaceutical development, established contract manufacturing infrastructure, and strong consumer health awareness drive significant market activity. The region benefits from sophisticated regulatory frameworks ensuring product quality and safety, leading pharmaceutical and nutraceutical companies, advanced manufacturing capabilities, and consumer preference for convenient dosage forms. Procaps Group's 2022 acquisition of United States production capacity demonstrates strategic expansion addressing growing domestic demand and strengthening North American manufacturing presence.Asia Pacific exhibits growth rates of 6.0%-8.5%, driven by expanding pharmaceutical manufacturing, growing dietary supplement markets, increasing healthcare spending, and rising consumer wellness awareness across China, India, Japan, and Southeast Asian countries. The region benefits from cost-competitive manufacturing, expanding middle class populations, increasing disposable incomes, and growing acceptance of preventive healthcare and dietary supplementation. China demonstrates rapid market expansion through domestic pharmaceutical production growth, expanding nutraceutical consumption, and developing contract manufacturing capabilities serving both domestic and export markets.
Europe demonstrates growth rates of 5.0%-7.0%, with established pharmaceutical industries, sophisticated dietary supplement markets, stringent regulatory standards, and strong consumer health consciousness across Germany, United Kingdom, France, and other advanced economies. The region emphasizes high-quality manufacturing, innovative formulation development, and premium product positioning. European manufacturers focus on specialty applications, advanced delivery technologies, and sustainable manufacturing practices aligned with environmental regulations and consumer preferences.
South America shows moderate growth rates of 4.5%-6.5%, with expanding pharmaceutical markets, growing dietary supplement adoption, increasing healthcare access, and rising middle class populations across Brazil, Argentina, and other countries. Procaps Group maintains significant regional presence serving pharmaceutical and nutraceutical manufacturers across South American markets.
The Middle East and Africa region exhibits growth rates of 4.0%-6.0%, with developing pharmaceutical sectors, growing dietary supplement awareness, increasing healthcare investment, and expanding consumer markets creating future growth opportunities as economic development and healthcare access improve.
Application Analysis
Drugs represent substantial market segments encompassing prescription pharmaceuticals and over-the-counter medications utilizing softgel delivery systems for enhanced bioavailability, dose precision, ingredient protection, and patient compliance. Pharmaceutical applications include cardiovascular medications, pain management products, hormonal therapies, vitamins and supplements formulated as drugs, and specialty therapeutic compounds benefiting from softgel encapsulation. Growth drivers include advancing pharmaceutical formulation science recognizing softgel advantages for poorly water-soluble active ingredients, expanding specialty drug development, increasing generic pharmaceutical production, growing preference for patient-friendly dosage forms, and rising healthcare expenditure globally supporting pharmaceutical consumption growth.Dietary supplement applications dominate softgel capsule consumption encompassing omega-3 fatty acids, vitamins and minerals, herbal extracts, probiotics, coenzyme Q10, and numerous nutritional ingredients serving health-conscious consumers. Supplements represent the largest and fastest-growing application segment driven by expanding global wellness trends, increasing preventive healthcare emphasis, growing aging populations seeking health maintenance products, rising disposable incomes enabling supplement purchases, and expanding scientific evidence supporting dietary supplementation benefits. Consumer preferences for convenient, easy-to-swallow dosage forms, precise dosing, and products free from artificial ingredients favor softgel formats.
Cosmetic applications represent emerging market segments encompassing beauty-from-within products including collagen supplements, hyaluronic acid formulations, antioxidant complexes, and specialty ingredients targeting skin health, hair quality, nail strength, and anti-aging benefits. Growth drivers include increasing consumer interest in holistic beauty approaches, expanding nutricosmetics category recognition, growing scientific support for oral beauty supplementation, and rising demand for natural and functional beauty products.
Key Market Players
Catalent Inc. operates global leadership in pharmaceutical and consumer health contract development and manufacturing including extensive softgel production capabilities across multiple continents. The company provides comprehensive services from formulation development through commercial manufacturing serving pharmaceutical, biotechnology, and consumer health companies worldwide. Catalent maintains advanced manufacturing technologies, regulatory expertise, and technical capabilities supporting complex formulation requirements.Capsugel Inc., historically a major softgel capsule manufacturer, was acquired by Lonza in 2017. Lonza announced in December 2024 its strategic decision to exit the Capsules & Health Ingredients business focusing exclusively on drug development and manufacturing services as a pure-play CDMO.
Soft Gel Technologies Inc. operates softgel contract manufacturing serving pharmaceutical, dietary supplement, and cosmetic companies requiring specialized encapsulation services. The company provides formulation development, analytical testing, and commercial production capabilities.
CAPTEK Softgel International Inc. manufactures softgel capsules and provides contract manufacturing services serving North American pharmaceutical and nutraceutical markets through specialized production capabilities and regulatory expertise.
Douglas Limited operates softgel manufacturing primarily serving United Kingdom and European markets with pharmaceutical and dietary supplement production capabilities.
Fuji Capsule Co. Ltd. manufactures softgel capsules in Japan serving domestic and international pharmaceutical and nutraceutical companies through advanced manufacturing technologies and quality systems.
Sirio Pharma Co. Ltd. sold 7,912,863,500 softgel capsules in 2024, demonstrating substantial production capacity and market presence. The Chinese manufacturer serves pharmaceutical, dietary supplement, and functional food applications through large-scale production facilities and expanding international customer relationships.
OneSource maintains annual production capacity reaching 2.4 billion capsules, ranking among top five global softgel producers. The company operates advanced manufacturing infrastructure serving pharmaceutical and nutraceutical markets.
Aenova Group provides contract development and manufacturing services for pharmaceuticals and dietary supplements including softgel production capabilities across European facilities serving global customers.
Procaps Group ranks among top five global pharmaceutical softgel producers, expanding through strategic acquisitions including January 2022 purchase of United States production facility with approximately 1.8 billion capsules annual capacity alongside research and development center strengthening integrated contract development and manufacturing organization capabilities.
Industry Value Chain Analysis
The softgel capsule industry value chain extends from raw material sourcing through specialized manufacturing and finished product distribution. Raw material procurement includes pharmaceutical-grade gelatin sourcing from qualified suppliers meeting stringent quality and safety standards, plasticizer procurement including glycerin and sorbitol, active pharmaceutical ingredients and dietary supplement materials requiring proper handling and storage, and excipients, colorants, and specialty ingredients supporting formulation requirements.Softgel manufacturing utilizes specialized rotary die encapsulation technology where gelatin ribbons are formed, filled, and sealed in continuous processes requiring precise temperature control, humidity management, and process parameter optimization. Manufacturing operations demand sophisticated capabilities including clean room environments meeting pharmaceutical production standards, advanced encapsulation equipment requiring skilled operation and maintenance, comprehensive quality control testing throughout production processes, and specialized drying and finishing operations ensuring capsule stability and quality.
Formulation development services support customers creating optimized softgel products through solubility enhancement, bioavailability improvement, stability testing, and analytical method development. Leading contract manufacturers invest substantially in technical expertise, pilot-scale equipment, and analytical capabilities supporting formulation optimization and regulatory documentation.
Quality assurance encompasses comprehensive testing including physical characterization, chemical analysis, microbiological testing, and stability studies ensuring products meet specifications and regulatory requirements. Regulatory compliance requires adherence to good manufacturing practices, quality management systems, documentation standards, and jurisdiction-specific requirements across pharmaceutical and dietary supplement applications.
Distribution channels include direct supply relationships between contract manufacturers and pharmaceutical or nutraceutical brand companies, finished product manufacturers operating internal softgel production for proprietary products, and contract packaging operations preparing finished consumer products from bulk softgel production.
Market Opportunities and Challenges
Opportunities
- Pharmaceutical Innovation and Specialty Drug Development: Advancing pharmaceutical research increasingly recognizes softgel delivery advantages for poorly water-soluble compounds, lipophilic active ingredients, and formulations requiring bioavailability enhancement. Manufacturers developing specialized softgel capabilities supporting complex pharmaceutical formulations, advanced delivery technologies, and regulatory expertise for new drug applications can capture premium pharmaceutical segments. Growing specialty pharmaceutical development, expanding generic drug production utilizing softgel formats, and increasing biologics and biosimilars potentially adapted to softgel delivery create substantial opportunities.
- Nutraceutical Market Expansion and Functional Foods: Expanding global dietary supplement consumption, growing consumer wellness emphasis, increasing preventive healthcare adoption, and rising functional food popularity create substantial softgel capsule demand. Manufacturers establishing positions in emerging supplement categories, developing innovative delivery systems, and providing comprehensive contract development and manufacturing services can capture growing nutraceutical markets. Omega-3 supplements, vitamin D, probiotics, and emerging ingredients including CBD, adaptogens, and novel botanicals present growth opportunities.
- Beauty-from-Within and Nutricosmetics: Emerging nutricosmetics category combining nutritional supplementation with beauty benefits creates opportunities for specialized softgel formulations delivering collagen, hyaluronic acid, antioxidants, and specialty ingredients supporting skin health, hair quality, and anti-aging benefits. Manufacturers developing expertise in cosmetic ingredient encapsulation, clinical substantiation, and consumer product positioning can establish early positions in high-growth, premium-priced market segments.
- Sustainable and Clean Label Innovations: Growing consumer demand for natural, sustainable, and clean label products creates opportunities for plant-based softgel alternatives, sustainable gelatin sourcing, and formulations minimizing synthetic additives. Manufacturers developing vegetarian or vegan softgel technologies, implementing sustainable sourcing practices, and achieving clean label formulations can differentiate offerings and capture environmentally conscious consumer segments.
Challenges
- Raw Material Sourcing and Cost Volatility: Softgel manufacturing requires pharmaceutical-grade gelatin subject to supply fluctuations, quality variability, and price volatility influenced by animal protein markets, regulatory changes, and global supply dynamics. Alternative capsule shell materials including plant-based options face availability constraints and cost premiums. Raw material challenges create cost pressures, supply uncertainties, and formulation constraints requiring supplier diversification and strategic sourcing approaches.
- Manufacturing Complexity and Capital Requirements: Softgel production demands specialized rotary die equipment requiring substantial capital investment, skilled technical operation, precise process control, and ongoing maintenance. Production scalability faces challenges from equipment limitations, process optimization requirements, and quality consistency demands. New market entrants face significant capital barriers and technical learning curves, while established manufacturers must continuously invest in capacity expansion, technology upgrades, and process improvements.
- Regulatory Compliance and Quality Standards: Pharmaceutical and dietary supplement applications require adherence to stringent good manufacturing practices, quality management systems, testing protocols, and documentation standards varying across jurisdictions. Regulatory complexity creates compliance costs, operational constraints, and potential liability risks. Manufacturers must maintain comprehensive quality systems, regulatory expertise, and documentation capabilities satisfying customer requirements and regulatory expectations across multiple markets.
- Competitive Intensity and Pricing Pressures: The softgel contract manufacturing industry experiences substantial competitive pressures from global capacity expansion, pricing competition particularly from Asian manufacturers, and customer negotiating leverage. Commodity softgel production faces margin pressures and limited differentiation opportunities, while specialty applications require technical capabilities and regulatory expertise not universally available. Manufacturers must balance competitive pricing, quality maintenance, and adequate returns on substantial capital investments.
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1: Executive SummaryChapter 2: Abbreviation and Acronyms
Chapter 3: Preface
Chapter 4: Market Landscape
Chapter 5: Market Trend Analysis
Chapter 6: industry Chain Analysis
Chapter 7: Latest Market Dynamics
Chapter 8: Trading Analysis
Chapter 9: Historical and Forecast Softgel Capsule Market in North America (2021-2031)
Chapter 10: Historical and Forecast Softgel Capsule Market in South America (2021-2031)
Chapter 11: Historical and Forecast Softgel Capsule Market in Asia & Pacific (2021-2031)
Chapter 12: Historical and Forecast Softgel Capsule Market in Europe (2021-2031)
Chapter 13: Historical and Forecast Softgel Capsule Market in MEA (2021-2031)
Chapter 14: Summary For Global Softgel Capsule Market (2021-2026)
Chapter 15: Global Softgel Capsule Market Forecast (2026-2031)
Chapter 16: Analysis of Global Key Vendors
List of Tables and Figures
Companies Mentioned
- Catalent Inc.
- Capsugel Inc.
- Soft Gel Technologies Inc.
- CAPTEK Softgel International Inc.
- Douglas Limited
- Fuji Capsule Co. Ltd.
- Medgel Pvt. Ltd.
- Bee Health Limited
- SOFTIGEL
- Shandong Yuwang Group
- Sirio Pharma Co. Ltd.
- OneSource
- Aenova Group
- Procaps Group
- EuroCaps
- HealthCaps India Limited
